Fundraising Fox

Pharvaris

4 known investors

Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema. It is a clinical-stage biopharmaceutical company focused on this rare disease area.

BiotechHealthtech

Investors · 4

Bain Capital Life SciencesBoston
Foresite CapitalWest Hollywood
Kurma PartnersParis · $162K – $10.8M
venBio PartnersSan Francisco

Founder mafia

2 people who came through Pharvaris went on to found or lead other companies.

Luc DochezCo-Founder and Board memberFounded Montis Biosciences +1Sanmay SaradaBiometric Data EngineerFounded Astraea

In the news

Is Pharvaris (PHVS) Undervalued After New Phase 3 Endpoint Research? - Simply Wall St Newssimplywall.st · Aug 2026Citizens raises Pharvaris stock price target to $75 on trial progress By Investing.comca.investing.com · Aug 2026Pharvaris posts Q2 loss, builds cash and late-stage pipeline | PHVS SEC Filing - Form 6-Kstocktitan.net · Aug 2026The Bull Case For Pharvaris (PHVS) Could Change Following Major Equity Raise And NDA Progress - Learn Why - Simply Wall St Newssimplywall.st · May 2026Pharvaris Equity Raise Supports Late Stage HAE Push And Valuation Casefinance.yahoo.com · May 2026Pharvaris Raises $132.3M in Upsized Share Offering — Pharvaris N.V. | BriefGlancebriefglance.com · May 2026

Frequently asked questions

What does Pharvaris do?
Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema. It is a clinical-stage biopharmaceutical company focused on this rare disease area.
Who are Pharvaris's investors?
Pharvaris's investors include Bain Capital Life Sciences, Foresite Capital, Kurma Partners, venBio Partners.